Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

BACKGROUND: Nivolumab has shown significant survival benefit and a favorable safety profile compared with dacarbazine chemotherapy among treatment-naïve patients with metastatic melanoma in the CheckMate 066 phase III study. Results from the health-related quality of life (HRQoL) analyses from Check...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035785/
https://www.ncbi.nlm.nih.gov/pubmed/27405322
http://dx.doi.org/10.1093/annonc/mdw265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035785/
https://www.ncbi.nlm.nih.gov/pubmed/27405322
http://dx.doi.org/10.1093/annonc/mdw265

Ejemplares similares